184 related articles for article (PubMed ID: 36625609)
41. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
43. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
[TBL] [Abstract][Full Text] [Related]
44. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
McVary KT
J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
[TBL] [Abstract][Full Text] [Related]
45. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
46. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Viktrup L; Hayes RP; Wang P; Shen W
BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of self-estimation of disuric disorders gauged IPSS scale and qualities of lives QoL with self-estimation of sexual life gauged by IIEF-5 scale].
Lipczyński W; Dobrowolska-Glazar B; Dobrowolski ZF
Przegl Lek; 2012; 69(6):247-52. PubMed ID: 23094437
[TBL] [Abstract][Full Text] [Related]
48. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Salah Azab S; Elsheikh MG
Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
[TBL] [Abstract][Full Text] [Related]
49. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
50. [A Study of the Efficacy of the Additional Administration of Tadalafil in Japanese Men with α1-Blocker-Resistant LUTS/BPH].
Hayashi K; Fukagai T; Sasaki H; Morita M; Igarashi A; Koshikiya A
Hinyokika Kiyo; 2016 Mar; 62(3):117-21. PubMed ID: 27133883
[TBL] [Abstract][Full Text] [Related]
51. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
[TBL] [Abstract][Full Text] [Related]
52. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
Cervenakov I; Fillo J
Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
[TBL] [Abstract][Full Text] [Related]
53. Prostatic Artery Embolization Allows to Maintain Full Sexual Activity in Patients Suffering from Bothersome Lower Urinary Tracts Symptoms related to Benign Prostatic Hyperplasia.
Marzano L; Thiounn N; Pereira H; Pellerin O; Dariane C; Del Giudice C; Amouyal G; Dean C; Sapoval M
Cardiovasc Intervent Radiol; 2020 Aug; 43(8):1202-1207. PubMed ID: 32494835
[TBL] [Abstract][Full Text] [Related]
54. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
55. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
[TBL] [Abstract][Full Text] [Related]
56. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
57. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
[TBL] [Abstract][Full Text] [Related]
58. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
60. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Woo HH; Bolton DM; Laborde E; Jack G; Chin PT; Rashid P; Thavaseelan J; McVary KT
J Sex Med; 2012 Feb; 9(2):568-75. PubMed ID: 22172161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
